Related Experiment Videos
Opioids induce while nicotine suppresses apoptosis in human lung cancer cells
1Simmons Cancer Center, Department of Medicine, University of Texas Southwestern Medical Center, Dallas 75235-8590.
Abstract:
Previously, we have shown that opioids acting via specific receptors inhibit the growth of human lung cancer cells while nicotine, acting through nicotinic acetylcholine receptors, reverses this inhibition. Therefore, we studied the role of apoptosis in these processes. Treatment of human lung cancer cells with 0.1-1 microM morphine or methadone resulted in morphological changes and cleavage of DNA into nucleosome-sized fragments characteristic of apoptosis. Quantitation of DNA fragmentation showed that a dose-dependent increase occurred within 2 h of opioid treatment and was blocked by the antagonist naloxone. The apoptotic effect of opioids was suppressed by nicotine, while the nicotinic acetylcholine receptor antagonists, hexamethonium and decamethonium, reversed this suppression. In contrast, sphingosine, a protein kinase C inhibitor, caused significant DNA fragmentation which was not suppressed by nicotine. Unexpectedly, the combination of hexamethonium and opioids or hexamethonium and nicotine stimulated apoptosis. We found that nicotine, like phorbol 12-myristate 13-acetate, increased total protein kinase C (PKC) activity, while morphine and sphingosine decreased PKC activity, and nicotine reversed morphine inhibition of PKC activity. In contrast, methadone unexpectedly increased PKC activity. These results indicate that engagement of opioid receptors in human lung cancer cells induces apoptosis, while engagement of nicotine receptors suppresses apoptosis, which in some cases appear to be working through a PKC pathway. They also suggest complexities in the system where blockade of C6 or C10 nicotinic receptors can lead to facilitation of apoptosis. These findings suggest new strategies for treatment and prevention of cancer using opioids or nicotine receptors antagonists and are consistent with the idea that nicotine functions as a tumor promoter.
Insights
Opioids induce apoptosis in human lung cancer cells, while nicotine suppresses it. Nicotine may promote cancer, suggesting new therapeutic strategies involving opioid and nicotine receptor antagonists.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Opioids inhibit human lung cancer cell growth via specific receptors.
- Nicotine, acting on nicotinic acetylcholine receptors, reverses opioid-induced growth inhibition.
- The role of apoptosis in these opposing effects requires elucidation.
Purpose of the Study:
- To investigate the role of apoptosis in opioid and nicotine interactions with human lung cancer cells.
- To explore the involvement of protein kinase C (PKC) signaling pathways.
- To identify potential therapeutic targets for cancer treatment and prevention.
Main Methods:
- Treatment of human lung cancer cells with morphine, methadone, nicotine, and receptor antagonists (naloxone, hexamethonium, decamethonium).
- Assessment of morphological changes and DNA fragmentation to quantify apoptosis.
- Measurement of protein kinase C (PKC) activity.
Main Results:
- Opioid treatment (morphine, methadone) induced apoptosis in a dose- and time-dependent manner, blocked by naloxone.
- Nicotine suppressed opioid-induced apoptosis; nicotinic antagonists reversed this suppression.
- Sphingosine induced apoptosis, unaffected by nicotine. Nicotine increased PKC activity, while morphine decreased it; methadone unexpectedly increased PKC activity.
- Combinations of hexamethonium with opioids or nicotine also stimulated apoptosis.
Conclusions:
- Opioid receptor engagement induces apoptosis in lung cancer cells.
- Nicotine receptor engagement suppresses apoptosis, potentially via PKC pathways, and may act as a tumor promoter.
- Nicotinic receptor blockade can paradoxically facilitate apoptosis, suggesting complex signaling interactions.
- Findings support novel cancer treatment strategies using opioid or nicotine receptor modulators.